Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affects systemic small vessels and is accompanied by the presence of ANCAs in the serum. This disease entity includes microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and drug-induced AAV. Similar to other autoimmune diseases, AAV develops in patients with a predisposing genetic background who have been exposed to causative environmental factors. The mechanism by which ANCAs cause vasculitis involves ANCA-mediated excessive activation of neutrophils that subsequently release inflammatory cytokines, reactive oxygen species and lytic enzymes. In addition, this excessive activation of neutrophils by ANCAs induces formation of neutrophil extracellular traps (NETs). Although NETs are essential elements in innate immunity, excessive NET formation is harmful to small vessels. Moreover, NETs are involved not only in ANCA-mediated vascular injury but also in the production of ANCAs themselves. Therefore, a vicious cycle of NET formation and ANCA production is considered to be involved in the pathogenesis of AAV. In addition to this role of NETs in AAV, some other important discoveries have been made in the past few years. Incorporating these new insights into our understanding of the pathogenesis of AAV is needed to fully understand and ultimately overcome this disease.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affects systemic small vessels and is accompanied by the presence of ANCAs in the serum.
AAV includes microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and drug-induced AAV.
AAV can develop in patients with a genetically predisposing background who are exposed to causative environmental factors, such as infectious agents, drugs and air pollutants.
ANCAs have a central role in the pathogenesis of AAV because they induce excessive activation of neutrophils, which results in injury to small vessels.
Other immune cells (such as dendritic cells, macrophages, B cells and T cells), the complement system and humoral factors are also involved in the pathogenesis of AAV.
Elucidation of the aetiology and pathogenesis of AAV is needed to develop new biomarkers as well as novel targeted therapeutic agents.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Davies, D. J., Moran, J. E., Niall, J. F. & Ryan, G. B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br. Med. J. (Clin. Res. Ed.) 285, 606 (1982).
Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 65, 1–11 (2013).
Fujimoto, S. et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology 50, 1916–1920 (2011).
Furuta, S. et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J. Rheumatol. 41, 325–333 (2014).
Furuta, S. et al. Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohorts. J. Rheumatol. 44, 216–222 (2017).
Pearce, F. A., Craven, A., Merkel, P. A., Luqmani, R. A. & Watts, R. A. Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 56, 1962–1969 (2017).
Seeliger, B. et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology 56, 1154–1161 (2017).
Bossuyt, X. et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat. Rev. Rheumatol. 13, 683–692 (2017).
Ntatsaki, E. et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology 53, 2306–2309 (2014).
Yates, M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 75, 1583–1594 (2016).
Puechal, X. et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol. 68, 690–701 (2016).
Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214–223 (2012).
Xie, G. et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum. 65, 2457–2468 (2013).
Rahmattulla, C. et al. Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann. Rheum. Dis. 75, 1687–1692 (2016).
Kawasaki, A. et al. Protective role of HLA-DRB1*13:02 against microscopic polyangiitis and MPO-ANCA-positive vasculitides in a Japanese population: a case–control study. PLOS ONE 11, e0154393 (2016).
Cao, Y. et al. High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. PLOS ONE 7, e42783 (2012).
Relle, M., Fohr, B., Fasola, F. & Schwarting, A. Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3. Mol. Cell. Probes 30, 366–373 (2016).
Ciavatta, D. J. et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J. Clin. Invest. 120, 3209–3219 (2010).
Jones, B. E. et al. Gene-specific DNA methylation changes predict remission in patients with ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 1175–1187 (2017).
Popa, E. R. et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatology 46, 1029–1033 (2007).
Gomez-Puerta, J. A., Gedmintas, L. & Costenbader, K. H. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun. Rev. 12, 1129–1135 (2013).
Yashiro, M. et al. Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am. J. Kidney Dis. 35, 889–895 (2000).
Takeuchi, Y. et al. The influence of the great East Japan earthquake on microscopic polyangiitis: a retrospective observational study. PLOS ONE 12, e0177482 (2017).
Farquhar, H. J. et al. Incidence of anti-neutrophil cytoplasmic antibody-associated vasculitis before and after the February 2011 Christchurch earthquake. Intern. Med. J. 47, 57–61 (2017).
Moodie, F. D., Leaker, B., Cambridge, G., Totty, N. F. & Segal, A. W. α-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int. 43, 675–681 (1993).
Yu, F. et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am. J. Kidney Dis. 49, 607–614 (2007).
Kain, R. et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 14, 1088–1096 (2008).
Nagao, T. et al. Direct activation of glomerular endothelial cells by anti-moesin activity of anti-myeloperoxidase antibody. Nephrol. Dial. Transplant. 26, 2752–2760 (2011).
Kontic, M., Radovanovic, S., Nikolic, M. & Bonaci-Nikolic, B. Concomitant drug- and infection-induced antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis with multispecific ANCA. Med. Princ. Pract. 21, 488–491 (2012).
Fukuhara, A. et al. Systemic vasculitis associated with anti-neutrophil cytoplasmic antibodies against bactericidal/permeability increasing protein. Intern. Med. 52, 1095–1099 (2013).
Suzuki, K. et al. A novel autoantibody against moesin in the serum of patients with MPO-ANCA-associated vasculitis. Nephrol. Dial. Transplant. 29, 1168–1177 (2014).
Shida, H. et al. The presence of anti-lactoferrin antibodies in a subgroup of eosinophilic granulomatosis with polyangiitis patients and their possible contribution to enhancement of neutrophil extracellular trap formation. Front. Immunol. 7, 636 (2016).
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535 (2004).
Grayson, P. C. & Kaplan, M. J. At the bench: neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J. Leukoc. Biol. 99, 253–264 (2016).
Schreiber, A. et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc. Natl Acad. Sci. USA 114, E9618–E9625 (2017).
Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl Acad. Sci. USA 107, 9813–9818 (2010).
Nakazawa, D. et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3779–3787 (2012).
Wada, N. et al. Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves’ disease treated with propylthiouracil and thiamazole. Endocr. J. 49, 329–334 (2002).
Lee, E. et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem. Pharmacol. 37, 2151–2153 (1988).
Sangaletti, S. et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 120, 3007–3018 (2012).
Hurtado, P. R. et al. CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol. 9, 34 (2008).
Nakazawa, D. et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J. Am. Soc. Nephrol. 25, 990–997 (2014).
Hiwa, R. et al. Myeloperoxidase/HLA class II complexes recognized by autoantibodies in microscopic polyangiitis. Arthritis Rheumatol. 69, 2069–2080 (2017).
Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002).
Huugen, D. et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am. J. Pathol. 167, 47–58 (2005).
Kanzaki, G. et al. Impact of anti-glomerular basement membrane antibodies and glomerular neutrophil activation on glomerulonephritis in experimental myeloperoxidase-antineutrophil cytoplasmic antibody vasculitis. Nephrol. Dial. Transplant. 31, 574–585 (2016).
Primo, V. C. et al. Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin. Exp. Immunol. 159, 327–337 (2010).
Little, M. A. et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLOS ONE 7, e28626 (2012).
Little, M. A. et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am. J. Pathol. 174, 1212–1220 (2009).
Brouwer, E. et al. Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J. Exp. Med. 177, 905–914 (1993).
Heeringa, P. et al. Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am. J. Pathol. 149, 1695–1706 (1996).
Ruth, A. J. et al. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J. Am. Soc. Nephrol. 17, 1940–1949 (2006).
Schreiber, A., Xiao, H., Falk, R. J. & Jennette, J. C. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J. Am. Soc. Nephrol. 17, 3355–3364 (2006).
Kusunoki, Y. et al. Peptidylarginine deiminase inhibitor suppresses neutrophil extracellular trap formation and MPO-ANCA production. Front. Immunol. 7, 227 (2016).
Kinjoh, K., Kyogoku, M. & Good, R. A. Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc. Natl Acad. Sci. USA 90, 3413–3417 (1993).
Jennette, J. C. & Falk, R. J. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat. Rev. Rheumatol. 10, 463–473 (2014).
Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115–4119 (1990).
Charles, L. A., Caldas, M. L., Falk, R. J., Terrell, R. S. & Jennette, J. C. Antibodies against granule proteins activate neutrophils in vitro. J. Leukoc. Biol. 50, 539–546 (1991).
Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623–625 (2009).
Kraaij, T. et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int. 94, 139–149 (2018).
Futamata, E. et al. Vanishing immunoglobulins: the formation of pauci-immune lesions in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Nephron 138, 328–330 (2018).
Yoshida, M., Sasaki, M., Sugisaki, K., Yamaguchi, Y. & Yamada, M. Neutrophil extracellular trap components in fibrinoid necrosis of the kidney with myeloperoxidase-ANCA-associated vasculitis. Clin. Kidney J. 6, 308–312 (2013).
O’Sullivan, K. M. et al. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney Int. 88, 1030–1046 (2015).
Gupta, S. & Kaplan, M. J. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat. Rev. Nephrol. 12, 402–413 (2016).
Fussner, L. A. et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 68, 1700–1710 (2016).
Fiedler, T. J., Davey, C. A. & Fenna, R. E. X-Ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8|Å resolution. J. Biol. Chem. 275, 11964–11971 (2000).
Suzuki, K. et al. Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol. Immunol. 51, 1215–1220 (2007).
Gou, S. J., Xu, P. C., Chen, M. & Zhao, M. H. Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis. PLOS ONE 8, e60530 (2013).
Yoshida, M. et al. Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis. Clin. Exp. Rheumatol. 27, S28–S32 (2009).
Roth, A. J. et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J. Clin. Invest. 123, 1773–1783 (2013).
Flint, S. M., McKinney, E. F. & Smith, K. G. Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol. 27, 197–203 (2015).
Abdulahad, W. H., Lamprecht, P. & Kallenberg, C. G. T-Helper cells as new players in ANCA-associated vasculitides. Arthritis Res. Ther. 13, 236 (2011).
Chavele, K. M. et al. Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum. 62, 1539–1548 (2010).
Wilde, B., Hoerning, A., Kribben, A., Witzke, O. & Dolff, S. Abnormal expression pattern of the IL-2 receptor β-chain on CD4+ T cells in ANCA-associated vasculitis. Dis. Markers 2014, 249846 (2014).
Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52–64 (2007).
Xiao, H. et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25, 225–231 (2014).
Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289–298 (2009).
Huang, Y. M., Wang, H., Wang, C., Chen, M. & Zhao, M. H. Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol. 67, 2780–2790 (2015).
Yuan, J. et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res. Ther. 14, R140 (2012).
Gou, S. J., Yuan, J., Chen, M., Yu, F. & Zhao, M. H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 83, 129–137 (2013).
Nakazawa, D., Tomaru, U. & Ishizu, A. Possible implication of disordered neutrophil extracellular traps in the pathogenesis of MPO-ANCA-associated vasculitis. Clin. Exp. Nephrol. 17, 631–633 (2013).
Kallenberg, C. G. Pathogenesis and treatment of ANCA-associated vasculitides. Clin. Exp. Rheumatol. 33 (Suppl. 92), S11–S14 (2015).
Nakazawa, D. et al. The responses of macrophages in interaction with neutrophils that undergo NETosis. J. Autoimmun. 67, 19–28 (2016).
Nishide, M. et al. Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis. Ann. Rheum. Dis. 76, 1440–1448 (2017).
Nishide, M. & Kumanogoh, A. The role of semaphorins in immune responses and autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 19–31 (2018).
Wang, H. et al. Circulating level of neutrophil extracellular traps is not a useful biomarker for assessing disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. PLOS ONE 11, e0148197 (2016).
Heeringa, P., Rutgers, A. & Kallenberg, C. G. M. The net effect of ANCA on neutrophil extracellular trap formation. Kidney Int. 94, 14–16 (2018).
Masuda, S. et al. NETosis markers: quest for specific, objective, and quantitative markers. Clin. Chim. Acta 459, 89–93 (2016).
Kallenberg, C. G., Stegeman, C. A., Abdulahad, W. H. & Heeringa, P. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. Am. J. Kidney Dis. 62, 1176–1187 (2013).
Kantari, C. et al. Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis. Blood 110, 4086–4095 (2007).
Millet, A. et al. Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. J. Clin. Invest. 125, 4107–4121 (2015).
Nogueira, E. et al. Serum IL-17 and IL-23 levels and autoantigen-specific TH17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 25, 2209–2217 (2010).
Lepse, N., Abdulahad, W. H., Kallenberg, C. G. & Heeringa, P. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun. Rev. 11, 77–83 (2011).
Csernok, E. et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for TH1 priming via the protease-activated receptor-2 pathway. Blood 107, 4440–4448 (2006).
Pendergraft, W. F. 3rd et al. Autoimmunity is triggered by cPR-3105–201, a protein complementary to human autoantigen proteinase-3. Nat. Med. 10, 72–79 (2004).
Stegeman, C. A. et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120, 12–17 (1994).
Comarmond, C. et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65, 270–281 (2013).
Bremer, J. P., Csernok, E., Holle, J., Gross, W. L. & Moosig, F. Getting rid of MPO-ANCA: a matter of disease subtype. Rheumatology 52, 752–754 (2013).
Khoury, P., Grayson, P. C. & Klion, A. D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 10, 474–483 (2014).
Polzer, K. et al. Eotaxin-3 is involved in Churg–Strauss syndrome — a serum marker closely correlating with disease activity. Rheumatology 47, 804–808 (2008).
Vaglio, A., Buzio, C. & Zwerina, J. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art. Allergy 68, 261–273 (2013).
Sullivan, S., Salapow, M. A., Breen, R. & Broide, D. H. Eosinophil peroxidase differs from neutrophil myeloperoxidase in its ability to bind antineutrophil cytoplasmic antibodies reactive with myeloperoxidase. Int. Arch. Allergy Immunol. 105, 150–154 (1994).
Okubo, K. et al. Lactoferrin suppresses neutrophil extracellular traps release in inflammation. EBioMedicine 10, 204–215 (2016).
Grau, R. G. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr. Rheumatol. Rep. 17, 71 (2015).
Olives, T. D., Kornas, R. L., Fujisawa, R. & Cole, J. B. Unexpected complication of cocaine-associated anti-neutrophil cytoplasmic antibody vasculitis related to persistent in-hospital cocaine use. J. Addict. Med. 11, 157–160 (2017).
Lood, C. & Hughes, G. C. Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity. Rheumatology 56, 638–643 (2017).
Irizarry-Caro, J. A. et al. Brief report: drugs implicated in systemic autoimmunity modulate neutrophil extracellular trap formation. Arthritis Rheumatol. 70, 468–474 (2018).
Schneeweis, C. et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin. Exp. Rheumatol. 28, 62–66 (2010).
Bader, L., Koldingsnes, W. & Nossent, J. B-Lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titer. Clin. Rheumatol. 29, 1031–1035 (2010).
Lenert, A. & Lenert, P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des. Devel. Ther. 9, 333–347 (2015).
Bontscho, J. et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J. Am. Soc. Nephrol. 22, 336–348 (2011).
Novikov, P., Moiseev, S., Bulanov, N. & Shchegoleva, E. Bortezomib in refractoryANCA-associated vasculitis: a new option? Ann. Rheum. Dis. 75, e9 (2016).
Langford, C. A. et al. An open-label trial of abatacept (CTLA4–Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann. Rheum. Dis. 73, 1376–1379 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00482066 (2015).
Arimura, Y. et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin. Nephrol. 40, 256–264 (1993).
Ohlsson, S., Wieslander, J. & Segelmark, M. Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediators Inflamm. 13, 275–283 (2004).
McAdoo, S. P. & Pusey, C. D. Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis? Nephrol. Dial. Transplant. 32, i80–i88 (2017).
Berti, A. et al. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin. Arthritis Rheum. 45, 48–54 (2015).
Wechsler, M. E. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 376, 1921–1932 (2017).
Chen, M., Jayne, D. R. W. & Zhao, M. H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 13, 359–367 (2017).
Huugen, D. et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 71, 646–654 (2007).
Jayne, D. R. W. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756–2767 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02994927 (2018).
de Luna, G. et al. Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: data from the French Vasculitis Study Group. J. Autoimmun. 65, 49–55 (2015).
Uechi, E., Okada, M. & Fushimi, K. Effect of plasma exchange on in-hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: a propensity-matched analysis using a nationwide administrative database. PLOS ONE 13, e0196009 (2018).
Espinasse, M. A. et al. Glucocorticoid-induced leucine zipper is expressed in human neutrophils and promotes apoptosis through Mcl-1 down-regulation. J. Innate Immun. 8, 81–96 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00987389 (2018).
The authors’ research was supported by a grant from the Japan Research Committee of the Ministry of Health, Labour and Welfare for intractable vasculitis.
Nature Reviews Rheumatology thanks F. Moosig and A. Rutgers, and other anonymous reviewers, for their contribution to the peer review of this work.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nakazawa, D., Masuda, S., Tomaru, U. et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15, 91–101 (2019). https://doi.org/10.1038/s41584-018-0145-y
Respiratory Investigation (2021)
Clinical usefulness of rituximab for early remission in anti-neutrophil cytoplasmic antibody associated vasculitis: a case report
Japanese journal of pediatric nephrology (2021)
Double-negative T cells are absolutely elevated in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis
Molecular Immunology (2021)
Muscle biopsy in anti-neutrophil cytoplasmic antibody–associated vasculitis: diagnostic yield depends on anti-neutrophil cytoplasmic antibody type, sex and neutrophil count
Frontiers in Immunology (2021)